The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of… Read More »The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).